Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 1225376
1. Wiwanitkit V: Nitric oxide synthase and polycystic kidney disease. J Nephropharmacol; 2015;4(2):85-87

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nitric oxide synthase and polycystic kidney disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28197487.001).
  • [Journal-full-title] Journal of nephropharmacology
  • [ISO-abbreviation] J Nephropharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Keywords] NOTNLM ; Chronic kidney disease / Nitric oxide synthase / Polycystic kidney disease
  •  go-up   go-down


2. American Society for Microbiology, Washington, DC, USA: Publisher's Expression of Concern: Lactobacillus bulgaricus Prevents Intestinal Epithelial Cell Injury Caused by Enterobacter sakazakii-Induced Nitric Oxide both <i>In Vitro</i> and in the Newborn Rat Model of Necrotizing Enterocolitis. Infect Immun; 2017 04;85(4)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Publisher's Expression of Concern: Lactobacillus bulgaricus Prevents Intestinal Epithelial Cell Injury Caused by Enterobacter sakazakii-Induced Nitric Oxide both <i>In Vitro</i> and in the Newborn Rat Model of Necrotizing Enterocolitis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ExpressionOfConcernFor] Infect Immun. 2009 Mar;77(3):1031-43 [19075027.001]
  • (PMID = 28336717.001).
  • [ISSN] 1098-5522
  • [Journal-full-title] Infection and immunity
  • [ISO-abbreviation] Infect. Immun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Sattarinezhad E, Panjehshahin MR, Torabinezhad S, Kamali-Sarvestani E, Farjadian S, Pirsalami F, Moezi L: Protective Effect of Edaravone Against Cyclosporine-Induced Chronic Nephropathy Through Antioxidant and Nitric Oxide Modulating Pathways in Rats. Iran J Med Sci; 2017 Mar;42(2):170-178

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protective Effect of Edaravone Against Cyclosporine-Induced Chronic Nephropathy Through Antioxidant and Nitric Oxide Modulating Pathways in Rats.
  • The present study evaluates the protective effect of edaravone on CsA-induced chronic nephropathy and investigates its antioxidant and nitric oxide modulating property.
  • The groups were categorized as: Group 2: Vehicle (n=10)Groups 3, 4, and 5: Edaravone (1, 5, and 10 mg/kg) (n=7 each)Group 6: Diphenyliodonium chloride, a specific endothelial nitric oxide synthase (eNOS) inhibitor (n=7)Group 7: Aminoguanidine, a specific inducible nitric oxide synthase (iNOS) inhibitor (n=7)Group 8: Edaravone (10 mg/kg) plus diphenyliodonium chloride (n=7)Group 9: Edaravone (10 mg/kg) plus aminoguanidine (n=7) Blood urea nitrogen and serum creatinine levels, malondialdehyde, superoxide dismutase, and glutathione reductase enzyme activities were measured using standard kits.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pharmacol Exp Ther. 1997 May;281(2):921-7 [9152402.001]
  • [Cites] J Cell Biochem. 2015 Mar;116(3):364-9 [25418335.001]
  • [Cites] J Histochem Cytochem. 2005 Dec;53(12):1459-68 [15956028.001]
  • [Cites] Free Radic Res. 2004 Apr;38(4):333-41 [15190930.001]
  • [Cites] Nature. 1988 Jun 16;333(6174):664-6 [3131684.001]
  • [Cites] Kidney Int. 1988 Feb;33(2):590-600 [3283402.001]
  • [Cites] Toxicology. 2003 Jul 15;189(1-2):99-111 [12821286.001]
  • [Cites] Free Radic Res. 1996 May;24(5):361-7 [8733940.001]
  • [Cites] Lancet. 1994 May 14;343(8907):1199-206 [7909873.001]
  • [Cites] Hypertension. 1994 Jun;23(6 Pt 2):957-61 [8206635.001]
  • [Cites] Vascul Pharmacol. 2013 Jan;58(1-2):134-9 [23107619.001]
  • [Cites] Drug Discov Today Dis Models. 2010;7(1-2):13-19 [21286234.001]
  • [Cites] BMC Musculoskelet Disord. 2013 Mar 27;14:113 [23530927.001]
  • [Cites] Int J Mol Sci. 2013 Jul 04;14(7):13909-30 [23880849.001]
  • [Cites] Shock. 2008 Dec;30(6):734-9 [18496239.001]
  • [Cites] Hypertension. 1997 Oct;30(4):934-41 [9336396.001]
  • [Cites] Life Sci. 2004 Jun 25;75(6):639-53 [15172174.001]
  • [Cites] J Clin Pathol. 1988 May;41(5):498-503 [3290264.001]
  • [Cites] Biochem J. 2001 Aug 1;357(Pt 3):593-615 [11463332.001]
  • [Cites] Kidney Int. 2001 Jan;59(1):87-95 [11135061.001]
  • [Cites] Kidney Int. 2004 May;65(5):1714-23 [15086910.001]
  • [Cites] Oxid Med Cell Longev. 2015;2015:804659 [25834700.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Nov;126(5):1461-6 [14666020.001]
  • [Cites] Transplant Proc. 2004 Mar;36(2 Suppl):229S-233S [15041343.001]
  • [Cites] Eur Heart J. 2012 Apr;33(7):829-37, 837a-837d [21890489.001]
  • [Cites] Acta Physiol (Oxf). 2006 Aug;187(4):433-46 [16866775.001]
  • [Cites] Anal Biochem. 1979 Jun;95(2):351-8 [36810.001]
  • [Cites] Curr Drug Metab. 2002 Feb;3(1):61-71 [11876576.001]
  • [Cites] Life Sci. 2000 Sep 29;67(19):2387-92 [11065185.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Oct;307(1):74-82 [12954792.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Eur J Pharmacol. 2003 Aug 22;476(1-2):131-7 [12969758.001]
  • [Cites] J Immunol. 2008 Aug 15;181(4):2831-45 [18684975.001]
  • (PMID = 28360443.001).
  • [ISSN] 0253-0716
  • [Journal-full-title] Iranian journal of medical sciences
  • [ISO-abbreviation] Iran J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Keywords] NOTNLM ; Cyclosporine / Edaravone / Kidney diseases / Nitric oxide / eNOSe / iNOS
  •  go-up   go-down


Advertisement
4. Ko SY, Chang YS, Park WS: Clinical response to inhaled nitric oxide in persistent pulmonary hypertension of the newborn. J Korean Med Sci; 1998 Oct;13(5):500-6
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical response to inhaled nitric oxide in persistent pulmonary hypertension of the newborn.
  • We observed clinical response to inhaled nitric oxide (iNO) in 12 neonates with persistent pulmonary hypertension of the newborn (PPHN).
  • Two infants showed no response to iNO (one diaphragmatic hernia and one suspected pulmonary hypoplasia).
  • We conclude that iNO therapy could improve oxygenation in high percentage of newborn infants with severe PPHN of various underlying conditions except pulmonary hypoplasia.
  • [MeSH-major] Nitric Oxide / therapeutic use. Persistent Fetal Circulation Syndrome / therapy. Vasodilator Agents / therapeutic use

  • Genetic Alliance. consumer health - Pulmonary Hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 9811179.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Vasodilator Agents; 31C4KY9ESH / Nitric Oxide
  • [Other-IDs] NLM/ PMC3054528
  •  go-up   go-down


5. Al-Ali MK, Howarth PH: Exhaled nitric oxide levels in exacerbations of asthma, chronic obstructive pulmonary disease and pneumonia. Saudi Med J; 2001 Mar;22(3):249-53
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exhaled nitric oxide levels in exacerbations of asthma, chronic obstructive pulmonary disease and pneumonia.
  • OBJECTIVE: Nitric oxide is known to be present in the exhaled air of normal subjects and at higher concentrations in asthmatics.
  • The aim of this study was to measure exhaled nitric oxide levels in patients admitted to hospital with acute exacerbations of asthma, or chronic obstructive pulmonary disease, or with pneumonia.
  • METHODS: Within 24 hours of admission exhaled nitric oxide levels were measured by a chemiluminescent analyzer in 11 patients with acute sever asthma, 19 patients with acute exacerbation of chronic obstructive pulmonary disease, and in 12 patients with pneumonia.
  • RESULTS: On admission median exhaled nitric oxide levels (range) were significantly higher in asthmatics 22 (9.3-74) parts per billion in comparison to patients with chronic obstructive pulmonary disease 10.3 (2.7-34) parts per billion; p < 0.01, pneumonia 7 (4-17) parts per billion; p<0.001, and normal subjects 8.7 (5-13.3) parts per billion; p < 0.001.
  • Following treatment the asthmatics had a significant reduction in their exhaled nitric oxide levels from 22 (9.3-74) parts per billion on day 1 to 9.7 (5.7-18.3) parts per billion on day 28; p = 0.005.
  • A strong negative correlation existed between peak expiratory flow rate measurements and exhaled nitric oxide levels in asthmatics on day 28 (r = -0.70; p = 0.017).
  • CONCLUSION: Acute exacerbations of asthma are associated with increased levels of exhaled nitric oxide in contrast to exacerbations of chronic obstructive pulmonary disease and acute pneumonia.
  • Exhaled nitric oxide may be a useful indirect marker of asthmatic airway inflammation.
  • The differing time course of response of nitric oxide to peak flow measures suggests that these two measures are reflecting differing airway events.
  • [MeSH-major] Asthma / metabolism. Breath Tests. Lung Diseases, Obstructive / metabolism. Nitric Oxide / analysis. Pneumonia / metabolism


6. Kozij NK, Granton JT, Silkoff PE, Thenganatt J, Chakravorty S, Johnson SR: Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease. Can Respir J; 2017;2017:6736239

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease.
  • Exhaled nitric oxide (eNO) is a potential biomarker to distinguish systemic sclerosis (SSc) associated pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD).
  • We evaluated the discriminative validity, feasibility, methods of eNO measurement, and magnitude of differences across lung diseases, disease-subsets (SSc, systemic lupus erythematosus), and healthy-controls. <i>Methods</i>.
  • Consecutive subjects in the UHN Pulmonary Hypertension Programme were recruited.
  • Exhaled nitric oxide was measured at 50 mL/s intervals using chemiluminescent detection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 1997 Sep;40(9):1725 [9324032.001]
  • [Cites] Chest. 2010 Sep;138(3):682-92 [20822990.001]
  • [Cites] Arthritis Res Ther. 2016 Jan 27;18:30 [26819137.001]
  • [Cites] Arthritis Rheum. 2013 Nov;65(11):2737-47 [24122180.001]
  • [Cites] N Engl J Med. 2013 Jul 25;369(4):330-40 [23883378.001]
  • [Cites] Thorax. 1997 Dec;52(12):1051-5 [9516898.001]
  • [Cites] N Engl J Med. 2009 Nov 5;361(19):1864-71 [19890129.001]
  • [Cites] J Rheumatol. 2000 Jul;27(7):1693-8 [10914853.001]
  • [Cites] Respir Med. 2000 Oct;94(10):985-91 [11059953.001]
  • [Cites] J Appl Physiol (1985). 1998 Aug;85(2):653-66 [9688744.001]
  • [Cites] Chest. 1999 May;115(5):1407-17 [10334161.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):732-3; author reply 732-3 [16107628.001]
  • [Cites] J Appl Physiol (1985). 1999 Oct;87(4):1532-42 [10517788.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Jun;163(7):1557-61 [11401873.001]
  • [Cites] Thorax. 2012 Feb;67(2):157-63 [22026971.001]
  • [Cites] Eur Respir Rev. 2011 Dec;20(122):277-86 [22130821.001]
  • [Cites] Chest. 1999 May;115(5):1352-6 [10334152.001]
  • [Cites] Chest. 2004 Jul;126(1 Suppl):7S-10S [15249491.001]
  • [Cites] Eur Respir J. 2000 Sep;16(3):555-60 [11028672.001]
  • [Cites] J Rheumatol. 2014 Nov;41(11):2193-200 [25274896.001]
  • [Cites] Rheumatology (Oxford). 2001 Apr;40(4):453-9 [11312386.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Jun 15;165(12):1587-91 [12070057.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Jun 1;177(11):1248-54 [18369202.001]
  • [Cites] Arthritis Rheum. 1982 Nov;25(11):1271-7 [7138600.001]
  • [Cites] Nitric Oxide. 2009 May;20(3):200-6 [19100854.001]
  • [Cites] J Rheumatol. 2010 Aug 1;37(8):1680-7 [20595271.001]
  • [Cites] Sarcoidosis Vasc Diffuse Lung Dis. 2009 Jul;26(1):32-8 [19960786.001]
  • [Cites] Eur Respir J. 2007 Jul;30(1):26-30 [17428812.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 1):1218-28 [10764315.001]
  • [Cites] Lancet. 1998 May 16;351(9114):1491-2 [9605813.001]
  • [Cites] Nitric Oxide. 2013 Jan 15;28:65-70 [23099297.001]
  • [Cites] Arthritis Res Ther. 2006;8(4):R104 [16813666.001]
  • [Cites] J Appl Physiol (1985). 2007 Jan;102(1):417-25 [16888048.001]
  • [Cites] J Rheumatol. 2012 Feb;39(2):276-85 [22247353.001]
  • [Cites] Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 62):S5-9 [21050538.001]
  • [Cites] Chest. 2007 Aug;132(2):575-80 [17550935.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Jun;163(7):1693-722 [11401895.001]
  • (PMID = 28293128.001).
  • [ISSN] 1916-7245
  • [Journal-full-title] Canadian respiratory journal
  • [ISO-abbreviation] Can. Respir. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


7. Stewart JM, Sutton R, Kothari ML, Goetz AM, Visintainer P, Medow MS: Nitric oxide synthase inhibition restores orthostatic tolerance in young vasovagal syncope patients. Heart; 2017 May 13;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nitric oxide synthase inhibition restores orthostatic tolerance in young vasovagal syncope patients.
  • We previously demonstrated impaired post-synaptic adrenergic responsiveness in young VVS patientswas reversed by blocking nitric oxide synthase(NOS).
  • We hypothesised that nitric oxide may account for reduced orthostatic tolerance in young recurrent VVS patients.
  • The data suggest that both pre- and post-synaptic arterial vasoconstriction may be affected by nitric oxide.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
  • (PMID = 28501796.001).
  • [ISSN] 1468-201X
  • [Journal-full-title] Heart (British Cardiac Society)
  • [ISO-abbreviation] Heart
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; neurologic events / pharmacology / vascular biology
  •  go-up   go-down


8. Albert M, Corsilli D, Williamson DR, Brosseau M, Bellemare P, Delisle S, Nguyen AQ, Varin F: Comparison of inhaled milrinone, nitric oxide and prostacyclin in acute respiratory distress syndrome. World J Crit Care Med; 2017 Feb 04;6(1):74-78

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of inhaled milrinone, nitric oxide and prostacyclin in acute respiratory distress syndrome.
  • METHODS: Open-label prospective cross-over pilot study where fifteen adult patients with hypoxemic failure meeting standard ARDS criteria and monitored with a pulmonary artery catheter were recruited in an academic 24-bed medico-surgical intensive care unit.
  • Thereafter, inhaled milrinone (1 mg/mL) alone followed by inhaled milrinone in association with inhaled nitric oxide (iNO) was administered.
  • RESULTS: The majority of ARDS were of pulmonary cause (<i>n</i> = 13) and pneumonia (<i>n</i> = 7) was the leading underlying initial disease.
  • Other pulmonary causes of ARDS were: Post cardiopulmonary bypass (<i>n</i> = 2), smoke inhalation injury (<i>n</i> = 1), thoracic trauma and pulmonary contusions (<i>n</i> = 2) and aspiration (<i>n</i> = 1).
  • Two patients had an extra pulmonary cause of ARDS: A polytrauma patient and an intra-abdominal abscess Inhaled nitric oxide, epoprostenol, inhaled milrinone and the combination of inhaled milrinone and iNO had no impact on systemic hemodynamics.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Crit Care Med. 1996 Mar;153(3):991-6 [8630585.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Mar 1;877(7):657-60 [19201666.001]
  • [Cites] J Intensive Care Med. 2006 May-Jun;21(3):119-43 [16672636.001]
  • [Cites] Intensive Care Med. 2009 Jan;35(1):171-8 [18972099.001]
  • [Cites] N Engl J Med. 1993 Feb 11;328(6):399-405 [8357359.001]
  • [Cites] Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 1):1671-7 [8970353.001]
  • [Cites] Can J Anaesth. 2005 Dec;52(10):1076-82 [16326679.001]
  • [Cites] Anesthesiology. 1995 Jun;82(6):1507-11 [7793662.001]
  • [Cites] Anesth Analg. 2011 Jun;112(6):1411-21 [21372277.001]
  • [Cites] N Engl J Med. 2005 Dec 22;353(25):2683-95 [16371634.001]
  • [Cites] Anesthesiology. 2002 Jun;96(6):1504-13 [12170067.001]
  • [Cites] Anesth Analg. 2001 Dec;93(6):1439-45, table of contents [11726420.001]
  • (PMID = 28224110.001).
  • [Journal-full-title] World journal of critical care medicine
  • [ISO-abbreviation] World J Crit Care Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Acute respiratory distress syndrome / Hypoxemia / Inhaled milrinone / Nitric oxide / Prostacyclin / Pulmonary hypertension
  •  go-up   go-down


9. Lahera V: Nitric oxide: A possible new biomarker in heart failure? Relationship with pulmonary hypertension secondary to left heart failure. Clin Investig Arterioscler; 2017 May - Jun;29(3):127-128

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nitric oxide: A possible new biomarker in heart failure? Relationship with pulmonary hypertension secondary to left heart failure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28499461.001).
  • [ISSN] 1578-1879
  • [Journal-full-title] Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
  • [ISO-abbreviation] Clin Investig Arterioscler
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


10. Rocha-Penha L, Caldeira-Dias M, Tanus-Santos JE, de Carvalho Cavalli R, Sandrim VC: Myeloperoxidase in Hypertensive Disorders of Pregnancy and Its Relation With Nitric Oxide. Hypertension; 2017 Jun;69(6):1173-1180

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloperoxidase in Hypertensive Disorders of Pregnancy and Its Relation With Nitric Oxide.
  • Elevated levels of myeloperoxidase have been demonstrated in women with preeclampsia where it may contribute to endothelial dysfunction mediated, in part, by nitric oxide impairment.
  • In this study, we investigated myeloperoxidase in hypertensive disorders of pregnancy and its contribution to the impairment of the vasodilator nitric oxide.
  • We found higher levels of myeloperoxidase in supernatant from human umbilical vein endothelial cells cultures incubated with plasma from preeclampsia group compared with healthy pregnant women.
  • Moreover, the inhibition of myeloperoxidase activity in vitro improved nitric oxide bioavailability.
  • Our results indicate a higher cardiovascular risk in pregnant women with hypertensive disorders, and that active myeloperoxidase may play a role in endothelial dysfunction in these conditions by impairment of nitric oxide availability.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • (PMID = 28461600.001).
  • [ISSN] 1524-4563
  • [Journal-full-title] Hypertension (Dallas, Tex. : 1979)
  • [ISO-abbreviation] Hypertension
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; cardiovascular diseases / heparin / human umbilical vein endothelial cells / nitric oxide / pregnancy
  •  go-up   go-down






Advertisement